Work

Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial

Year: 2026

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Abstract: BACKGROUND: The number of cancer survivors is growing rapidly, and >70% are overweight or obese. Given their increased risk for obesity-related conditions (eg, cardiovascular disease, second malignancies), weight-loss interventions are a priority for this population, yet few have access. PATIENTS AND METHODS: We conducted a 2-arm, single-blinded, randomized controlled trial to test whether a 24-week, fully automated, web-based diet intervention would significantly improve body weight and other health-related outcomes compared with a waitlist control among cancer survivors. The AiM, PLan, and act on LIFestYles (AMPLIFY) diet intervention offered serialized, tailored guidance to achieve a 0.5 kg per week weight loss and improve diet quality. Survivors of 1 of 9 obesity-related cancers with >70% 5-year survival, aged ≥50 years, and with a body mass index of 25 to <50 kg/m2 enrolled in the trial across the United States (n=349). Participants were randomly assigned to the AMPLIFY-Diet intervention (n=151) or waitlist control (n=198). The primary outcome was weight loss; secondary outcomes included other health indices and diet quality. Intervention delivery and assessments (baseline, 3 months, and 6 months) occurred from 2020 to 2024. RESULTS: Intent-to-treat analyses showed significantly greater weight loss among intervention versus waitlist participants (percent weight change, -4.75%; 95% CI, -6.04% to -3.46%), with higher proportions attaining 3%, 5%, and 10% weight loss benchmarks (P<.001 for all). Significant between-arm differences were also observed for waist circumference (-3.47 cm; 95% CI, -4.86 to -2.08; P<.001), circulating leptin (-2,050.5 pg/mL; 95% CI, -3,049.5 to -1,051.6; P<.001), cognitive function (2.22; 95% CI, 0.30 to 4.15; P=.02), and systolic blood pressure (intention-to-treat: -3.54 mm Hg; 95% CI, -7.30 to 0.27; P=.07, sensitivity analysis: -5.10 mm Hg; 95% CI, -9.09 to -1.10; P=.013). Furthermore, significant decreases in caloric intake (-288 kcal/d; 95% CI, -391.5 to -184.6; P<.001) and improvements in diet quality were observed. CONCLUSIONS: The magnitude of weight loss achieved with AMPLIFY is the highest reported to date for any fully automated intervention and produced significant benefits. Continued optimization and research to integrate the AMPLIFY-Diet intervention into broader use and clinical practice are warranted.

Source: Journal of the National Comprehensive Cancer Network

DOI: 10.6004/jnccn.2026.7012